One thousand lots of pooled fetal bovine serum (FBS) were tested for contamination with bovine viral diarrhea virus (BVDV) and/or for contamination with neutralizing antibody against BVDV. Noncytopathic or cytopathic BVDV was isolated from 203 lots of FBS. Analysis of the viral isolates identified 115 type 1 and 65 type 2 BVDV isolates. An additional 23 virus isolates were mixtures of Ն2 BVDV isolates and were not classified to viral genotype. Further characterization of the type 1 viruses identified 51 subgenotype 1a and 64 subgenotype 1b BVDV isolates. Viral neutralizing antibody was detected in 113 lots of FBS. Differential viral neutralization indicated that type 1 BVDV induced the antibody detected in 48 lots of FBS and type 2 BVDV induced the antibody detected in 16 lots of FBS.
The bovine viral diarrhea virus (BVDV) is a widely distributed single-stranded, positive-sense RNA virus that infects cattle of all ages. Currently, BVDV is classified in the Pestivirus genus of the family Flaviviridae. 44 Pestiviruses include hog cholera virus of swine and border disease virus (BDV) of sheep, both of which are antigenically related to BVDV. Disease manifestations induced by BVDV vary and include respiratory, reproductive, and/or enteric disorders. 4 Usually, disease induced by BVDV is mild, but severe to fatal disease may occur. In cell culture, BVDV may be noncytopathic or cytopathic in biotype. 18, 22 Cytopathic BVDV isolates are rare and usually are coisolated with noncytopathic BVDV from tissues collected postmortem from cattle that die of mucosal disease. 5, 8, 12, 26 Cytopathic BVDV isolates arise from noncytopathic BVDV after a mutational event in the viral RNA triggers expression of an 80-kD nonstructural peptide that is unique to the cytopathic viral biotype. 16, 19, 24, 25, 29, 30, 33, 36 Although cytopathic BVDV isolates have received considerable attention from researchers, the predominating noncytopathic BVDV isolates induce most outbreaks of disease. Recently, virulent noncytopathic BVDV isolates have emerged that can cause substantial death loss and have focused attention on control practices for BVDV. 1, 2, 10, [13] [14] [15] 20, 31, 32 Comparison of nucleic acid sequences from virulent BVDV with comparable sequences from vaccine and laboratory reference viruses led to segregation of BVDV into 2 viral genotypes, type 1 and type 2 BVDV. 28, 35 Further segregation of type 1 BVDV into 1a and 1b subgenotypes appears warranted based on analysis of nucleic acid sequences from numerous isolates of BVDV. 27, 28, 35 Type 1 and type 2 BVDV are antigenically different from each other, and that difference may allow type 2 BVDV to escape the immune response stimulated by inactivated vaccines that contain only type 1 BVDV. 6, 35 In addition to being a ubiquitous viral pathogen of cattle, noncytopathic BVDV is a common contaminant of fetal bovine serum (FBS), which is used to supplement growth medium for cell cultures. 7, 17, 21, 23, 38 This contamination presents a problem for diagnostic laboratories because noncytopathic BVDV isolates infect a variety of cell cultures and may interfere with diagnosis of disease. 11, 17, 23, 38, 43 Several years ago, a survey of FBS was conducted to determine the prevalence of BVDV and antibody against BVDV in pooled FBS. 7 Approximately 31% of 1,608 samples of pooled sera (pools of sera from 2 or 3 fetuses) were contaminated with BVDV and/or antibody against BVDV. Segregation of BVDV into genotypes and emergence of virulent noncytopathic BVDV have occurred since that survey was done. Also, there is some indication that vaccination against BVDV has increased, especially in dairy operations. 40, 41 Increased use of vaccine might lead to a decreased rate of contamination of FBS with BVDV. In this study, FBS was examined for contamination with BVDV and/or antibody against BVDV. The purpose was to determine the prevalence and distribution of BVDV genotypes in FBS that was harvested in the midwestern United States during 1995 and 1996. Additionally, an attempt was made to determine the viral genotype that stimulated virus neutralizing antibody detected in FBS and to find evidence for infection of bovine fetuses with BDV.
Materials and methods
Fetal bovine serum. FBS was harvested by a commercial supplier a of raw serum from abattoirs in Illinois, Minnesota, and South Dakota that processed dairy and beef cattle. This supplier of fetal bovine serum also was used in a previous survey. 7 After harvest, FBS was pooled into 1-liter lots (n ϭ 1,000) containing sera from 1-3 fetuses. Records for identification of the dam of a fetus or the farm of origin of a dam were not kept by the supplier. A 70-ml aliquot from each lot of FBS was frozen and shipped to the National Animal Disease Center (NADC) for testing. Upon arrival at the NADC, the FBS was thawed, centrifuged at 5,000 ϫ g for 1 hr, and passed through a 0.22-m filter. The filtrate was used for virus isolation and for detection of antibody against virus. Virus isolation. A 60-ml aliquot of FBS was mixed 1:1 with minimum essential medium (MEM) and inoculated onto bovine turbinate (BT) cells that had been seeded into a 490-cm 2 roller bottle. After 14 days of incubation at 37 C, the roller bottle was frozen and thawed. A 1-ml aliquot of thawed material from the roller bottle was inoculated into a 25-cm 2 flask freshly seeded with BT cells. After 5 days, a 50-l aliquot of medium from the flask was inoculated into a microtitration plate well that contained BT cells and 100 l of MEM supplemented to 10% with FBS known to be free of BVDV and antibody against BVDV. 7 After 24 hr of incubation at 37 C in a humidified atmosphere of 5.5% CO 2 in air, 25 l of medium from the microtitration plate well was used to inoculate a second well containing BT cells. After an additional 24 hr of incubation, the microtitration plate was drained, rinsed in tap water, and fixed for 10 min at room temperature with 40% acetone in phosphate-buffered saline (pH 7.6) containing 0.02% bovine serum albumin. Indirect immunoperoxidase staining was used to detect viral antigen in the BT cells. 7 An appropriate dilution of bovine hyperimmune serum in binding buffer was used as antibody. 7 The hyperimmune serum was tested previously and found to react with antigen produced by type 1 BVDV, type 2 BVDV, and BDV.
Viral genotyping. Initially, viruses were segregated into genotypes and subgenotypes based on nucleic acid sequence analysis and/or nested polymerase chain reaction (PCR) amplification. The primer set CAT-GCC-CAT-AGT-AGG-AC (forward primer) and CCA-TGT-GCC-ATG-TAC-AG (reverse primer) was used for first round PCR amplification and cycle sequencing. This primer set amplifies sequences from the genomic 5Ј untranslated region of type 1 and type 2 BVDV but does not appear to amplify sequences from BDV. Protocols used to make the viral RNA template, perform reverse transcriptase reactions, amplify viral sequences, and derive the nucleic acid sequence have been described. 35 A nested PCR reaction was used to differentiate types 1 and 2 BVDV. 35 Phylogenetic analysis of derived sequences was done using the MacDNAsis b software package.
Subsequent antigenic characterization of viruses genetically segregated to subgenotype 1a, subgenotype 1b, or genotype 2 revealed that monoclonal antibody (MAb) could be used to segregate BVDV to viral genotype. A panel of three MAbs, CA-1, BZ-30, and BZ-52, usually was sufficient for identification of viral genotype. The MAbs were produced against type 1 BVDV (CA-1, BZ-30) or type 2 BVDV (BZ-52) as described previously. 9 The MAbs CA-1 and BZ-30 were specific for type 1 BVDV, and BZ-52 was specific for type 2 BVDV. Further, MAB BZ-30 was specific for the 1b subgenotype of BVDV. An immunoperoxidase staining procedure was used for identification of viral genotype. Three adjacent wells containing infected BT cells were inoculated with 1 MAb each. Spent medium harvested from hybridoma cell cultures was the source of the MAbs. The spent medium was diluted 1:1 with binding buffer and added to wells for a 1-hr incubation at room temperature. After washing nonbound MAb from the wells, goat antiserum against mouse gamma globulin c was diluted 1:60 in binding buffer and added to the wells for a 30-min incubation at room temperature. The wells were washed again, and the staining procedure was completed as previously described. 7 An expanded panel of 29 MAbs was used for antigenic analysis of cytopathic viral isolates.
Detection and specificity of virus neutralizing antibody. A standard microtitration virus neutralization procedure was used for detection of virus neutralizing antibody in FBS. 39 Duplicate serial 2-fold dilutions of FBS were mixed with approximately 100 cell culture infective doses of genotype 1 BVDV-Singer, genotype 2 BVDV-125C, or a BDV, BDV-CB5C. The BVDV isolates were cytopathic in BT cells and the BDV was cytopathic in ovine turbinate (OT) cells; the end point of viral neutralizing antibody titer was determined after 5 days by microscopic examination of cells for cytopathic effect. Virus neutralizing antibody was considered stimulated by a specific viral genotype when the titer against that viral genotype was Ͼ8-fold higher than it was against representatives of other pesitiviral genotypes.
Controls. The BT and OT cells used in this study were free of adventitious BVDV as determined by immunoperoxidase staining and PCR. 11 Positive and negative controls for PCR were RNA extracted from BT cells infected with BVDV-NADL or BVDV-890 and RNA extracted from noninfected BT cells, respectively.
Results
Noncytopathic BVDV was isolated from 198 lots of FBS, and cytopathic BVDV was isolated from 5 lots of FBS (Table 1) . Nucleic acid sequence analysis, viral genotype-specific PCR, and MAb binding identified 110 noncytopathic viral isolates and 5 cytopathic viral isolates as type 1 BVDV. Patterns of reactivity with 29 MAbs indicated that 2 cytopathic viral isolates like-ly were BVDV-C24V and 1 cytopathic viral isolate likely was BVDV-Singer. To confirm the identity of those isolates, nucleic acid sequences were derived from the 5Ј untranslated region of each virus. The sequences matched those derived from BVDV-C24V or BVDV-Singer strains isolated from commercially available modified live virus vaccines. The remaining 2 cytopathic viral isolates were genetically and antigenically distinct from vaccine viruses used in the United States.
The MAb BZ-30 reacted with 64 noncytopathic BVDV isolates identified as belonging to genotype 1 by PCR. Results from nucleic acid sequence analysis of 9 of those isolates and of 16 type 1 BVDV isolates that did not react with BZ-30 agreed with previous unpublished findings that indicated BZ-30 was specific for BVDV subgenotype 1b. Thus, using MAb binding assay and/or nucleic acid sequence analysis, the 115 type 1 BVDV isolates were segregated into 46 noncytopathic and 5 cytopathic isolates of BVDV subgenotype 1a and 64 noncytopathic isolates of BVDV subgenotype 1b.
Nucleic acid sequence analysis, PCR, and MAb binding identified noncytopathic BVDV isolates from 65 lots of FBS as type 2. Virus isolated from an additional 23 lots of FBS could not be definitively assigned to a viral genotype by methods used in the current study. Those isolates likely were mixtures of 2 or more BVDV genotypes, suspected for several reasons: 1) multiple bands and/or weakly stained bands were observed after electrophoresis of PCR amplicons from RNA obtained from those viral isolates, 2) nucleic acid sequence analysis indicated presence of multiple bases at a specific genomic location, and 3) MAb binding patterns indicated that multiple viral genotypes and/or subgenotypes infected the BT cells. Considering the number of virus isolations made, and the fact that the FBS was pooled, detection of Ն2 BVDV genotypes in individual lots of FBS was not surprising.
Virus neutralizing antibody in 133 lots of FBS ranged in titer from 2 to 4,096 against type 1 BVDV or type 2 BVDV. In 64 of the 133 lots of FBS, virus neutralizing antibody against BDV ranged in titer from 2 to 128. In this study, virus neutralizing antibody titer that was highest by Ͼ8-fold against a specific viral genotype compared with representatives of other pestiviral genotypes was considered to have been stimulated by that viral genotype. Using that criterion, 48 lots of FBS contained antibody stimulated by type 1 BVDV and 16 lots of FBS contained antibody stimulated by type 2 BVDV (Table 1 ). The viral genotype that stimulated neutralizing antibody in 69 lots of FBS was not determined because the difference between the highest and second highest titer of antibody was not Ͼ8-fold. In 20 of those 69 lots of FBS, the neutralizing antibody titer was Ͻ8 against each of the viruses tested.
Virus was isolated from 7 lots of FBS that had neutralizing antibody titer of 2-128 against 1 genotype of BVDV and 0 against the other viral genotype. The BVDV isolated from 5 of those lots of FBS was of the viral genotype against which virus neutralizing antibody was not detected. Subgenotype 1b BVDV was isolated from 2 lots of FBS that had a virus neutralizing antibody titer of 2 or 16 against BVDV-Singer, a subgenotype 1a virus. Neutralizing antibody against genotype 2 BVDV, or against BDV, was not detected in those 2 lots of FBS.
Discussion
In the current study, BVDV was isolated from 203 of 1,000 (20.3%) lots of FBS, and virus neutralizing antibody against BVDV was detected in 133 (13.3%) lots of FBS. Essentially, the results from this survey of FBS were identical to those obtained 7 years previously when BVDV was isolated from 20.6% of lots of FBS and antibody against BVDV was detected in 13.9% of lots of FBS. 7 Methods for differentiation of BVDV genotypes had not been established when the previous survey of FBS was conducted. Therefore, 1 of the goals of the current study was to characterize the BVDV isolated from FBS at the genetic level, using PCR tests for detection of viral genotypes, and at the antigenic level, using MAb specific for viral genotypes and subgenotypes. Nucleic acid sequencing of select isolates of BVDV was done to confirm the validity of results from MAb binding and PCR amplifications. The methods used allowed segregation of most viral isolates into genotypes and subgenotypes. Type 1 BVDV was isolated from FBS about twice as frequently as was type 2 BVDV, 115 and 65 viral isolates, respectively. Further segregation of 115 type 1 BVDV into subgenotypes yielded 51 subgenotype 1a BVDV and 64 subgenotype 1b BVDV. Thus, the distribution of each of the subgenotypes of type 1 BVDV in FBS was similar to that of type 2 BVDV. Both subgenotypes of type 1 BVDV have been present in the United States for several decades. The 1a viral subgenotype includes commonly used laboratory reference and vaccine strains: BVDV-C24V, BVDV-NADL, and BVDV-Singer. The 1b viral subgenotype includes BVDV-NY-1, a noncytopathic BVDV that was isolated in 1948. 3 Because identification of type 2 BVDV has been recent, 28, 35 it is tempting to speculate that type 2 BVDV is a ''new'' virus and is still spreading in the cattle population, which would explain the less frequent isolation of type 2 BVDV than type 1 BVDV (type 1a and type 1b combined) from FBS. Another possible explanation for the uneven distribution of type 1 and type 2 BVDV in FBS is the en-hanced virulence associated with some type 2 BVDV isolates. Enhanced virulence might cause an increased abortion rate following fetal infection, which would result in fewer infected fetuses surviving until the dam was slaughtered.
An interesting finding in this study was the isolation of cytopathic BVDV from 5 lots of FBS. Biologic cloning at limiting dilution did not yield a noncytopathic BVDV associated with any of the cytopathic virus isolates. Failure to coisolate a noncytopathic BVDV with a cytopathic BVDV makes it unlikely that the cytopathic virus could be attributed to fetal mucosal disease. 5, 8, 12 Thus, the cytopathic BVDV isolated from FBS likely originated from an acute fetal infection. Using both nucleic acid sequence analysis of the 5Ј untranslated region of the viral RNA and MAb binding assay, 35 3 cytopathic BVDV isolates were identified as vaccine viruses (BVDV-C24V, BVDV-Singer). The fetuses harboring those viruses likely were infected following vaccination of a pregnant cow or exposure of a pregnant cow to a recently vaccinated animal. Two cytopathic BVDV isolates were genetically and antigenically distinct from vaccine viruses used in the United States. The origin of those 2 isolates is unknown.
To determine the viral genotype that stimulated production of virus neutralizing antibody detected in FBS, a differential virus neutralization test was used that included cytopathic type 1 BVDV, cytopathic type 2 BVDV, and cytopathic BDV. Previous experience indicated that this test will accurately identify the viral genotype that stimulates production of neutralizing antibody in convalescent serum obtained after experimental infection of cattle. The viral genotype that stimulated antibody production was identified for about half of the lots of FBS that contained virus neutralizing antibody. Type 1 BVDV stimulated fetal antibody production about 4 times more often than did type 2 BVDV. Thus, from analysis of viruses isolated from FBS and of antibody detected in FBS, it appears that in the midwestern United States infection of pregnant cattle with type 1 BVDV is more common than infection with type 2 BVDV.
In Europe, BDV appears to be circulating in the swine population. 37, 42 Hence, an attempt was made to find evidence for infection of cattle with BDV by isolation of BDV from FBS or by detection of antibody in FBS that had been stimulated by BDV. Testing of several known isolates of BDV indicated that BDV would not react with the MAb used in this study. Further, the nucleic acid sequence of BDV differs from that of BVDV, so the PCR test used in this study would yield a negative result. 34 All viral isolates in this study reacted with the MAb and/or were detected by the PCR test. Similarly, there was no indication that virus neutralizing antibody detected in FBS was stimulated by BDV. If BDV infects cattle in the midwestern United States, the results of this study suggest that it likely is an uncommon event.
